AstraZeneca PLCAZN:LSE

4,334.5
18.00 / 0.42%
1.72m
35.03%
0.3988
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 23 2014 16:59 BST.

Consensus recommendation

As of Oct 21, 2014, the consensus forecast amongst 66 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy8
Outperform8
Hold22
Underperform9
Sell8
No opinion0

Research Reports

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials

Dividends

In 2013, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.79 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Jul 31, 2014, AstraZeneca plc reported 2nd quarter 2014 earnings of 1.30 per share. This result exceeded the 1.10 consensus of the 13 analysts covering the company and exceeded last year's 2nd quarter results by 8.33%.
The next earnings announcement is expected on Nov 06, 2014. View Full Interim Financials

Average growth rate+2.18%

AstraZeneca plc reported annual 2013 earnings of 5.05 per share on Feb 06, 2014.
The next earnings announcement from AstraZeneca plc is expected the week of Feb 05, 2015. View Full Annual Financials

Average growth rate-4.07%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

AstraZeneca PLC had 2nd quarter 2014 revenues of 6.45bn. This bettered the 6.29bn consensus of the 13 analysts covering the company. This was 0.59% above the prior year's 2nd quarter results. View Full Interim Financials

Average growth rate+1.03%

AstraZeneca PLC had revenues for the full year 2013 of 25.71bn. This was 8.09% below the prior year's results. View Full Annual Financials

Average growth rate-5.61%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.